Oral Paricalcitol in Kidney Transplant Recipients
Completed · Not applicable
Conditions studied: Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
In brief
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this medication. The main possible benefits being studied are: * Lower risk for overactive parathyroid glands after kidney transplantation. * Lower risk of low bone density in the spine and hip after kidney transplantation. By dividing patients in the study into a group receiving Zemplar® and a group not receiving Zemplar®, it will be possible to understand the good and bad effects of Zemplar® during the first year after a kidney transplant.
Key facts
- Study ID
- NCT00587158
- Run by
- Mayo Clinic
- People needed
- 100
- Starts
- 2007-01-01
- Expected to finish
- 2011-11-01
- Last updated by the study team
- 2013-05-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 years and older.
- First or second deceased donor or living donor renal transplant.
- Normocalcemia or hypocalcemia.
- Willing to give informed consent
You may not qualify if…
- Third or subsequent renal transplant.
- Incompatible blood type or positive cross-match donor.
- Multiple organ transplant recipients.
- Diabetic with plans for future pancreas or islet transplant.
- Evidence of donor-specific sensitization (positive T-cell and/or B-cell flow cytometric cross-match).
- Documented hypercalcemia (total serum calcium 10.5 mg/dl on two separate occasions) prior to transplantation.
- Serum 25(OH)vitamin D concentration ≤ 10 ng/ml
Where it is running
- Mayo Clinic — Scottsdale, Arizona, United States
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.